Avacta agrees Affimer reagent licensing deal with New England

Royalty bearing license agreement to commercialise a product incorporating the Affimer technology

Wetherby and Cambridge, UK, 10 October 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes for molecular biology applications, to commercialise a product using the Affimer technology for use in both life science research and diagnostics assays.

Avacta and NEB have been collaborating to develop Affimers to combine with NEB’s reagents.  Avacta has identified Affimers that specifically inhibit certain NEB proprietary enzymes to provide modulation of their activity in response to temperature.  Unlike alternative enzyme inhibitors, Affimers can be fine-tuned to switch at the right temperature without having a negative effect on the overall assay performance. NEB is in the final stages of product testing and the two companies have agreed terms under which NEB will commercialise the combined product.

Financial details of the agreement are not being disclosed, but Avacta will receive a royalty on product sales, which may occur as soon as 2019.

NEB and Avacta expect to continue the collaboration to generate Affimer tools and inhibitors to other enzymes, enabling further product developments.

Alastair Smith, Chief Executive of Avacta Group commented: “We are delighted that the collaboration with New England Biolabs, a highly respected, globally recognized leader in the life sciences reagents market, has resulted in this commercial agreement to incorporate the Affimer technology into one of their products.

This is another important milestone for Avacta, because it further validates the Affimer technology and our licensing business model.  We have built a pipeline of evaluations and collaborations, such as this one with New England Biolabs, to deliver numerous license agreements to commercialise Affimer-based products. Collectively, these royalty bearing licenses will underpin the future high margin revenue from Affimer reagents.

We are looking forward to continuing our collaboration to generate more combined products for the research and molecular diagnostic markets.

This is a very exciting time for the Group and we look forward to updating the market on continuing commercial progress for Affimer reagents and, importantly, on therapeutic licensing deals.”

Media Contact Information: 

Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer

Tel:  +44 (0) 844 414 0452

Zyme Communications (Trade and Regional Media)
Katie Odgaard

finnCap Ltd
Geoff Nash / Giles Rolls - Nominated Adviser
Tim Redfern / Nikita Jain - Corporate Broking

WG Partners

Nigel Birks / Nigel Barnes
David Wilson / Claes Spang

Tel: +44 (0)7787 502 947

Tel:  +44 (0) 207 220 0500

Tel:  +44 (0) 203 705 9318
Tel:  +44 (0) 203 705 9217

Yellow Jersey (Financial Media and IR)
Sarah Hollins
Katie Bairsto

Tel: +44 (0)7764 947137
Tel: +44 (0)7946 424 651